Atrium Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 8.26 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 141.29M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company’s development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license a...